Staefa, Switzerland— The Sonova Group of hearing brands introduced new products and enhancements from Phonak, Unitron, and Advanced Bionics at the AAA show in Boston, including a new Lyric generation that will fit 50% more patients.


Phonak’s next generation of its Lyric extended wear hearing aids has a reduced size that will increase the anatomical fit rate by 50%. Lyric can be worn for up to 4 months without removing the device or changing batteries.

In addition, Phonak’s Spice+ technology will now be available in four performance levels, including the new "Essential" level. Essential is based on the Spice+ technology, but will have a reportedly competitive price. The Essential line includes a new product family named Phonak Dalia, as well as an entry-level model of the Audéo S SMART I and Naída S I. With Essential, Phonak is targeting mild to profound hearing loss endusers who are seeking value without compromising on the latest technology and state-of-the-art features.


Unitron introduced two new premium products, the Quantum Pro and Moxi Pro.
Built on the company’s Era platform, Quantum Pro and Moxi Pro feature binaural spatial processing and SpeechZone for improved hearing experience and speech understanding in challenging listening environments.

Unitron also expanded its Quantum family of custom products with its smallest-ever custom micro CIC. Unitron designed the product for first time wearers, reportedly offering a fully automatic, natural listening experience and a quick fit.

Advanced Bionics (AB)

Sonova’s Advanced Bionics (AB) division featured ClearVoice, a new speech enhancement technology for its cochear implants that was recently cleared by the FDA. Built on AB’s proprietary HiRes Fidelity 120 technology, ClearVoice has been designed to automatically analyze and adapt to each listening situation encountered throughout the day of a cochlear implant wearer, separating the distracting noises from speech.

ClearVoice is already approved in Europe, Canada, and China, and Sonova said in its press release that ClearVoice is the first and only speech enhancement technology available in the cochlear implant market. However, the company noted that ClearView was not currently approved for pediatric use in the United States.

SOURCE: Sonova